আয়ার্লণ্ড - ইংরেজি - HPRA (Health Products Regulatory Authority)

ssl international plc - glycol monosalicylate methyl nicotinate - cutaneous spray solution - 6.0/1.6 %w/v

আয়ার্লণ্ড - ইংরেজি - HPRA (Health Products Regulatory Authority)

ssl international plc - mepyramine maleate benzocaine - cutaneous spray solution - 1/0.5 %w/w

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

optimed technologies pty ltd - 11305 - drain, wound - superseton is a drain specifically designed for use in the drainage of perianal fistula.

ইস্রায়েল - ইংরেজি - Ministry of Health

takeda israel ltd - darvadstrocel - suspension for injection - darvadstrocel 5000000 cells/ml - darvadstrocel - alofisel is indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. alofisel should be used only after conditioning of the fistulas.

আয়ার্লণ্ড - ইংরেজি - HPRA (Health Products Regulatory Authority)

ssl international plc - benzocaine - cutaneous spray solution - 1 %w/w

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - palonosetron hydrochloride, quantity: 280 microgram (equivalent: palonosetron, qty 250 microgram) - injection, solution - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; hydrochloric acid; sodium hydroxide - palonosetron injection is indicated for prevention of nausea and vomiting induced by cytotoxic chemotherapy.

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

seton pharmaceuticals llc - butalbital (unii: khs0az4jvk) (butalbital - unii:khs0az4jvk), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - butalbital, acetaminophen and caffeine capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. caution in this regard is required because butalbital is habit-forming and potentially abusable. this product is contraindicated under the following conditions: - hypersensitivity or intolerance to any component of this product. - patients with porphyria. abuse and dependence butalbital barbiturates may be habit-forming : tolerance, psychological dependence, and physical dependence may occur especially following prolonged use of high doses of barbiturates. the average daily dose for the barbiturate addict is usually about 1500 mg. as tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than two-fold. as this occurs, the margin between an intoxication dosage and fatal dosage becomes smaller. the lethal dose of a barbiturate is far less if alcohol is also ingested. major withdrawal symptoms (convulsions and delirium) may occur within 16 hours and last up to 5 days after abrupt cessation of these drugs. intensity of withdrawal symptoms gradually declines over a period of approximately 15 days. treatment of barbiturate dependence consists of cautious and gradual withdrawal of the drug. barbiturate-dependent patients can be withdrawn by using a number of different withdrawal regimens. one method involves initiating treatment at the patient's regular dosage level and gradually decreasing the daily dosage as tolerated by the patient.

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

seton pharmaceuticals, llc - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone 5 mg in 5 ml - prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. dermatologic diseases pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (stevens-johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. edematous states to induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid su

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

seton pharmaceuticals - sulfacetamide (unii: 4965g3j0f5) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide 100 mg in 1 ml - 10% sodium sulfacetamide 5% sulfur cleanser (in a urea vehicle) is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. 10% sodium sulfacetamide 5% sulfur cleanser (in a urea vehicle) is contraindicated for patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. 10% sodium sulfacetamide 5% sulfur cleanser (in a urea vehicle) is not to be used by patients with kidney disease.

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

seton pharmaceuticals - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - fluocinolone acetonide 0.01% topical oil (scalp oil) is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. this product contains refined peanut oil nf (see precautions section). pediatric use: fluocinolone acetonide 0.01% topical oil may be used twice daily for up to 4 weeks in pediatric patients 2 years and older with moderate to severe atopic dermatitis. fluocinolone acetonide 0.01% topical oil should not be applied to the diaper area. application to intertriginous areas should be avoided due to the increased possibility of local adverse events such as striae, atrophy, and telangiectasia, which may be irreversible. the smallest amount of drug needed to cover the affected areas should be applied. long term safety in the pediatric population has not been established. fluocinolone acetonide 0.01% topical oil is not recommended for use on the face (see adverse reactions section). because of a higher ratio of skin surface area to body mass, children are at a greater risk than adults of hpa-axis-suppression when they are treated with topical corticosteroids. they are therefore also at greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of cushing's syndrome while on treatment. adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. (see precautions). hpa axis suppression, cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. children may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to acth stimulation. manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. fluocinolone acetonide 0.01% topical oil is formulated with 48% refined peanut oil nf. peanut oil used in this product is routinely tested for peanut proteins through amino acid analysis; the quantity of amino acids is below 0.5 parts per million. physicians should use caution in prescribing fluocinolone acetonide 0.01% topical oil for peanut sensitive individuals.